Guillaume Costecalde
About
Guillaume Costecalde is from France. Guillaume works in the following industries: "Biotechnology Research". Guillaume is currently Chairman at Human Cell Design, located in Toulouse, Occitanie, France. Guillaume also works as Chairman at PhysioStim, a job Guillaume has held since Jun 2020. Another title Guillaume currently holds is Président at Nubbo L'Incubateur. In Guillaume's previous role as a Chairman at Univercell-Biosolutions, Guillaume worked in Toulouse, Occitanie, France until Jun 2021. Prior to joining Univercell-Biosolutions, Guillaume was a Chairman at Physiogenex and held the position of Chairman at Toulouse, Occitanie, France. Prior to that, Guillaume was a Phrmaceutical and Biotechnologies Attaché at Ambassade de France aux Etats-Unis, based in Région de Washington DC from Feb 2000 to Aug 2003. Guillaume started working as Business Intelligence Developer at ObeTherapy in Paris et périphérie in Oct 1999. From Feb 1999 to Sep 1999, Guillaume was Finance and Strategy at Genopole, based in Paris et périphérie.
You can find Guillaume Costecalde's email at finalscout.com. FinalScout is a professional database with business professional profiles and company profiles.
Guillaume Costecalde's current jobs
Human Cell Design experts help you deliver better therapies to patients faster. At Human Cell Design, we assist industrials and academic groups by providing unique physiologically relevant human cell models.
PhysioStim is an independent preclinical CRO with high-level expertise in the field of cardiovascular pharmacology and electrophysiology.
Né dans le contexte de la loi sur l’innovation et la recherche du 12 juillet 1999 (loi Allègre), l’Incubateur est rapidement devenu un acteur incontournable de la création d’entreprise innovante en région Midi-Pyrénées, et aujourd’hui en Occitanie. NUBBO est une association loi 1901, réunissant la plupart des acteurs économiques et académiques de la région Occitanie en lien avec la création d’entreprises innovantes.
Cell-Easy is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides quick and easy access to ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. Our production process has been optimized under cGMP conditions, in order to be scalable and guarantee optimal product safety, quality and efficacy for your patients.